Detalhe da pesquisa
1.
Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia.
Blood
; 141(17): 2114-2126, 2023 Apr 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36720090
2.
Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Nature
; 566(7745): E11-E12, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30755741
3.
HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Nature
; 554(7691): 189-194, 2018 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29420467
4.
Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug-Drug Interaction Study.
Mar Drugs
; 22(4)2024 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38667795
5.
In Silico Transcriptomic Expression of MSR1 in Solid Tumors Is Associated with Responses to Anti-PD1 and Anti-CTLA4 Therapies.
Int J Mol Sci
; 25(7)2024 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38612803
6.
Genomic and Immunologic Correlates in Prostate Cancer with High Expression of KLK2.
Int J Mol Sci
; 25(4)2024 Feb 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38396898
7.
A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours.
Br J Cancer
; 128(8): 1418-1428, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36797356
8.
Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors.
Br J Cancer
; 129(2): 309-317, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37237172
9.
A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors.
Invest New Drugs
; 41(1): 93-104, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36538259
10.
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.
Cancer Immunol Immunother
; 71(2): 417-431, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34216247
11.
Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors.
Invest New Drugs
; 40(6): 1263-1273, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35947247
12.
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.
Invest New Drugs
; 40(4): 762-772, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35467243
13.
A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours.
Br J Cancer
; 124(2): 391-398, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33020594
14.
Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Oncologist
; 26(9): e1508-e1513, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33942954
15.
Toxicity and antitumor activity of novel agents in elderly patients with cancer included in phase 1 studies.
Invest New Drugs
; 39(6): 1694-1701, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34287771
16.
Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study.
Invest New Drugs
; 39(5): 1275-1283, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33704620
17.
A Predictive Score of Antitumour Activity of Novel Agents in Cancer Patients Treated in Early Phase Studies.
Oncology
; 99(7): 454-463, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33784674
18.
New approach to cancer therapy based on a molecularly defined cancer classification.
CA Cancer J Clin
; 64(1): 70-4, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24249308
19.
Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study.
Int J Gynecol Cancer
; 31(11): 1428-1436, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34610971
20.
Increased vulnerability of clinical research units during the COVID-19 crisis and their protection.
Cancer
; 126(17): 3907-3911, 2020 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32557596